TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of operationally defined outbursts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in corneal fluorescein staining (inferior region, Ora Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-selected Floor Walking Velocity Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Solicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of eyes with a ≥ 2-step improvement in DRSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Expression of clock genes in adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical Site Occurrences or Wound-related Events
Endpoint domain: Adverse events/effects
Primary endpoint: Spare respiratory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxygen consumption rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean 24 hours systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inter- and intra-rater agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in skin glycosaminoglycan (GAG) content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in skin sodium content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in plasma concentrations of methylmalonic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasma concentrations of holotranscobalamin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasma concentrations of homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasma concentrations of vitamin B12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment outcome in patients with erythema migrans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of hearing loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ADAS-COG Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Patients Who Demonstrate a Response to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain following arthroscopic surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function following arthroscopic surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Numeric Rating Scale (NRS) pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: all cause mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: ventilation free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in UPDRS Subscale II and III Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Treatment-Related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Successful Preparation Rated by Colonoscopist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Hard Tissue Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of opioid prescriptions per month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Spatial location of the pupil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in 6-Minute Walking Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the partial pressure of carbon dioxide (PaCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Death Cases
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of MA-negative urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of complications (access site bleeding)
Endpoint domain: Adverse events/effects
Primary endpoint: ADDQoL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative VAS score <4 at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Biomarker Values, ECG Results or Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Irritation as Assessed by the Local Tolerability Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Changes on fecal microbiome diversity at day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes on fecal microbiome abundance at day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes on fecal microbiome stability at day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of SARS-CoV-2 in breastmilk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of SARS-CoV-2 antibody in breastmilk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incident of major mobility disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Second-Line Progression-Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Assessment of tumor biological features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: All-cause 30-day mortality
Endpoint domain: Mortality/survival
Primary endpoint: Safety of the easyEndoTM Universal Linear Cutting Stapler
Endpoint domain: Adverse events/effects
Primary endpoint: cessation of rectal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Achievement of sustained virological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of RAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-24h)/24 h of serum cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 24 h urinary cortisol excretion adjusted for creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Side to side difference in peak stance phase knee adduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Side to side difference in peak stance-phase knee external rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Side to side difference in peak stance-phase anterior tibial translation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean Change From Baseline in Total S-STREAM Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Change From Baseline in Total S-STREAM Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Total S-STREAM Score, by Category
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of target reached
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brain Atrophy Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adherence to Anti-Retroviral Therapy (ART) at the End of 12-Week Intervention Period
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to Anti-Retroviral Therapy (ART) at the End of 16 Weeks (4-week Post-intervention Period)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Headache impact test (HIT-6)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life assessment (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants Achieving Dose Titration Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Dose Titration Phase in the Mean Visual Analog Scale (VAS) Score at Double Blind Phase
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nonfatal Ischemic Stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reductions in binge eating symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reductions in disordered eating symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reductions in body image symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Pharmacotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Progression Free Survival (PFS) at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Scale for the Assessment of Negative Symptoms (SANS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post meal blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical tolerable dose of celecoxib
Endpoint domain: Adverse events/effects
Primary endpoint: Estradiol blood concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Risk of mortality at day 30
Endpoint domain: Mortality/survival
Primary endpoint: changes in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Panic Disorder Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol response levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ultrasound velocity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jankovic Rating Scale sum-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of inhalation pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in metabolic activity in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improved parameters regarding inflammation associated with active lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in mEASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to Achieve Physical Therapy Discharge Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite clinical endpoint score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline WOMAC Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Knee Flexion Moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Walking Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Change in Incontinence Episode Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Volume of the Masseter Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage Change in Volume of the Parotid Gland
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Sweat Chloride Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of pharyngeal carriers of Group A streptococcus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of 6 meter walking speed at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of 6 meter walking speed at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total Mechanical Ventilation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in TLFS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful VL ordering
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: VL turnaround time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Occurrence of Post-randomization Cardiovascular Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 5-HIAA levels in PRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-HIAA levels in 24-hour urine collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of composite efficacy failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of EA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of induction therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximal diaphragm thickening fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of blood blasts at diagnosis of MPAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of medullar blasts at diagnosis of MPAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Classification of MPAL according to the WHO 2008 criteria at diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Local Progression-free Survival (LPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Regional Progression-free Survival (RPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Distant Metastasis-free Survival (DMFS)
Endpoint domain: Mortality/survival
Primary endpoint: Response rate of HAM-D17
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Glasgow Outcome Scale Extended (GOSe)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life in Brain Injury Overall Scale (QOLIBRI-OS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of Smokers Seen Who Enroll in the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Counseling Sessions Completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Who Are Rehospitalized for Psychiatric Reasons
Endpoint domain: Adverse events/effects
Primary endpoint: Occupancy of risperidone/olanzapine at the dopamine D2 receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in average TNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective experience parameters
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Children's self-reported adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to perform sit to stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to perform five time sit-to-stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C/EBPa-Bmi-1 axis in human lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in anti-KLH IgG antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects with treatment-emergent abnormalities in vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory-confirmed COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Telemetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants attaining tumor lesion with dosimetry >=2000 cGy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Adherence to Daily Device Use
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of Maximum Tolerated Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of My MS Toolkit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of My MS Toolkit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Response to therapy (complete and partial response rates)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive performance as measured by the MATRICS Consensus Cognitive Battery (MCCB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuroimage changes in Magnetic Resonance Imaging (MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Achievement of Optimal PTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development, frequency, and severity of hand-foot syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ELISPOT response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in IgG titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Caloric and protein intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pre- and post-intervention anthropometric measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous bleeding from oesophageal varices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: primary symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: assistant examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients diagnosed with collagen related pulmonary fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Balance on force plate platform
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total cost per patient per year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Location of the injected sterile, atmospheric air
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful coil embolization of the target intracranial aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of Serious Adverse Device Effects (SADE)
Endpoint domain: Adverse events/effects
Primary endpoint: Cost of healthcare resources
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Suspected Recurrent DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Suspected (recurrent) pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in acne lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total acne severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Difference in adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Validated AID Associated Product Technical Failures (PTFs)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of intraoperative and perioperative adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of hypercapnia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of unplanned all-cause hospitalisations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Color change (∆E)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TBR as measured by FDG-PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevated serum syndecan-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuro-modulation of immune system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes